Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:47 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
NCT04317781 · M.D. Anderson Cancer Center · PHASE2 · terminated · last registry update 2024-07-31 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The protocol was terminated early due to slow participant accrual and the sponsor not willing to provide the study drug.” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL3RA within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-01-30Also stopped (terminated): Gruppo Italiano Malattie EMatologiche dell'Adulto, tagraxofusp (NCT04342962)
- 2025-01-06Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp Injection (NCT02268253)
- 2024-12-06Results posted on the registry: Washington University School of Medicine, Flotetuzumab (NCT04582864)
- 2024-12-06Also stopped (terminated): Washington University School of Medicine, Flotetuzumab (NCT04582864)
- 2024-10-17Also stopped (terminated): Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-21Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp-erzs (NCT02270463)
- 2024-08-01Results posted on the registry: Stemline Therapeutics, Inc., Tagraxofusp (NCT02113982)
- 2024-04-17Also stopped (terminated): Stemline Therapeutics, Inc., SL-401 7 µg/kg/day + SL-401 9 µg/kg/day (NCT02661022)
- 2024-03-08Also stopped (withdrawn): Jonsson Comprehensive Cancer Center, Azacitidine + Tagraxofusp-erzs (NCT05720988)
- 2024-01-30Results posted on the registry: MacroGenics, Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off + Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (NCT02152956)
- 2024-01-30Also stopped (terminated): MacroGenics, Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off + Flotetuzumab 10 ng/kg/day, 4 days on and 3 days off (NCT02152956)
- 2023-12-11Results posted on the registry: Children's Oncology Group, Cytarabine + Flotetuzumab (NCT04158739)
- 2023-11-09Results posted on the registry: Stemline Therapeutics, Inc., SL-401 7 µg/kg/day + SL-401 9 µg/kg/day (NCT02661022)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision